甲氨蝶呤在越南银屑病关节炎患者中的有效性、安全性及耐受性
Effectiveness, Safety and Tolerance of Methotrexate in Vietnamese Psoriatic Arthritis Patients.
作者信息
Thi Van Bui, Minh Vinh Ngo, Ngoc Anh Tran, Dang Quyet Tran, Ngoc Diep Le, Van Em Dang, Van Thuong Nguyen, Minh Phuong Pham Thi, Thu Hien Do Thi, Huu Nghi Dinh, Huyen My Le, Hau Khang Tran, Gandolfi Marco, Satolli Francesca, Feliciani Claudio, Tirant Michael, Vojvodic Aleksandra, Lotti Torello
机构信息
Military Central Hospital, Hanoi City, Vietnam.
Pham Ngoc Thach University of Medicine, HCMC, Vietnam.
出版信息
Open Access Maced J Med Sci. 2019 Jan 27;7(2):250-252. doi: 10.3889/oamjms.2019.063. eCollection 2019 Jan 30.
AIM
To access the effectiveness, safety and tolerance of methotrexate (MTX) in psoriatic arthritis (PsA) treatment.
METHODS
We recruit 37 patients, admitted at HCMC Hospital of Dermato-Venereology from 1/2016 to 3/2017, with MTX dosage ranging from 10 mg to 15 mg per week.
RESULTS
Skin lesion response after 12 weeks improved PASI 50: 40.5%, PASI 75: 24.3%. Disease activity score decreased after 12 weeks with ∆DAS28 = -1.43 + 0.79, 37.8% PsA achieved complete remission. Nausea and vomiting were 8.1%. These symptoms were mild and transient. We did not stop MTX usage. The rate of elevating SGPT 2-3 times as much as the upper limit of the normal range was 2.7%.
CONCLUSION
We finally demonstrated that the rate of treatment response in Vietnam is the same as demonstrated by foreign authors in other countries.
目的
评估甲氨蝶呤（MTX）治疗银屑病关节炎（PsA）的有效性、安全性和耐受性。
方法
我们招募了37例患者，于2016年1月至2017年3月在胡志明市皮肤病与性病医院入院，MTX剂量为每周10毫克至15毫克。
结果
12周后皮肤病变反应改善，PASI 50改善率为40.5%，PASI 75改善率为24.3%。12周后疾病活动评分下降，∆DAS28 = -1.43 + 0.79，37.8%的PsA患者实现完全缓解。恶心和呕吐发生率为8.1%。这些症状轻微且短暂。我们未停止MTX使用。谷丙转氨酶升高至正常范围上限2至3倍的发生率为2.7%。
结论
我们最终证明越南的治疗反应率与其他国家的外国作者所证明的相同。
Zotero 插件